News Search Results
Sep 08, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule
More news about: Klotho Neurosciences, Inc.
Sep 08, 2025, 07:00 ET Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Sep 08, 2025, 07:00 ET Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
References: 1. Bennouna J. Lancet Oncol (14):29-37, 2013 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results
More news about: Oncolytics Biotech® Inc.
Sep 08, 2025, 06:55 ET Centrifuge Market worth $0.63 billion by 2030 - Exclusive Report by MarketsandMarkets™
centrifuge market is the increasing demand for efficient separation and purification processes across diverse industries, particularly pharmaceuticals, biotechnology, food and beverage, chemicals, and wastewater treatment. In pharmaceuticals and biotech, centrifuges are essential for applications such as cell
More news about: MarketsandMarkets
Sep 08, 2025, 06:45 ET Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 08, 2025, 06:35 ET Transcatheter Aortic Valve Replacement (TAVR) Market to Reach USD 14.06 Billion by 2035, with CAGR 6.9% Driven by Aging and Minimally Invasive Heart Procedures - Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 08, 2025, 03:41 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
KER-0193 was discovered and developed by Kaerus Bioscience, a UK headquartered biotechnology company co-founded by Medicxi in 2016. Kaerus Bioscience successfully completed a Phase 1 clinical study of KER-0193 in healthy volunteers in
More news about: Servier
Sep 08, 2025, 03:39 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
KER-0193 was discovered and developed by Kaerus Bioscience, a UK headquartered biotechnology company co-founded by Medicxi in 2016. Kaerus Bioscience successfully completed a Phase 1 clinical study of KER-0193 in healthy volunteers in
More news about: Servier
Sep 08, 2025, 00:15 ET Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines
it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics'
More news about: Sirnaomics
Sep 07, 2025, 22:00 ET Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
As a pioneering biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, Epigenic has
More news about: Epigenic Therapeutics
Sep 06, 2025, 11:05 ET BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
Prescribing Information, including Boxed Warning. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Sep 06, 2025, 10:15 ET Antibody Discovery Market worth US$3.54 billion by 2030 with 13.3% CAGR | MarketsandMarkets™
the demand for antibodies with improved efficacy, safety, and manufacturability profiles suitable for clinical development. Pharmaceutical and biotechnology companies frequently utilize engineering and optimization services to refine initial antibody leads generated through screening platforms, ensuring
More news about: MarketsandMarkets
Sep 05, 2025, 22:49 ET UNCY Investors: If you Lost Significant Money in UNCY Contact Robbins LLP for Information About the Securities Fraud Class Action Against Unicycive Therapeutics, Inc.
securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S.
More news about: Robbins LLP
Sep 05, 2025, 17:00 ET BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Sep 05, 2025, 10:30 ET Mabwell Secures Pakistan's First Denosumab Injection Approval
Pakistan's leading pharmaceutical companies, with eight state-of-the-art manufacturing facilities, including a dedicated biotechnology plant. With operations in over 20 countries and rapid expansion across multiple global regions, Searle is committed to delivering innovative treatments
More news about: Mabwell
Sep 05, 2025, 10:15 ET Hearing Aids Market is Expected to Reach US$45.68 Billion by 2031; Record a CAGR of 6.9% during the forecast period | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Logo:
More news about: The Insight Partners
Sep 05, 2025, 10:01 ET With 7.9% CAGR; Functional Safety Market Experiences Growth Owing to Increased Automation Across Industries by 2031 | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
More news about: The Insight Partners
Sep 05, 2025, 08:49 ET ZINZINO AB (PUBL.): LETTER OF INTENT TO ACQUIRE TRUVY FOR INCREASED DISTRIBUTION POWER IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Truvy is a global direct sales company in the health segment,
More news about: Zinzino
Sep 05, 2025, 08:37 ET Refrigeration Cooler Market Size is Projected To Reach US$7.48 Billion By 2031 at 6.4% GAGR |The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
More news about: The Insight Partners
Sep 05, 2025, 08:30 ET How Digital Cleaning Validation Improves OEE and Reduces Costs, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 05, 2025, 08:30 ET Clinical Research in LATAM: From a Standalone Site to a Regional Network, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 05, 2025, 08:30 ET Advanced Therapy Safety Management: Proactive Strategies for Real-World Risk Detection, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 05, 2025, 08:00 ET Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893
inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential. Braveheart Bio is a newly launched, U.S.-based biotechnology company focused on cardiovascular disease with a consortium of lead investors that includes Forbion, OrbiMed, and others. Under the terms
More news about: Jiangsu Hengrui Pharmaceuticals Co., Ltd
Sep 05, 2025, 07:05 ET REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Sep 05, 2025, 04:09 ET Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list.
More news about: Immunofoco